胸腔内灌注治疗肺癌相关胸腔积液的研究进展
Advances in the Treatment of Pleural Effusion Associated with Lung Cancer by Intrathoracic Perfusion
摘要: 恶性胸腔积液是晚期恶性肿瘤常见并发症之一，可引起胸痛、呼吸困难等症状，严重影响患者生活质量。临床上常用的治疗方法主要以胸腔置管引流积液为主，虽然可以及时缓解呼吸困难的症状，但现在无法从根本上治疗胸腔积液生成的问题。随着对恶性胸腔积液的深入研究，在胸腔置管引流积液的基础上联合药物胸腔内局部灌注是目前临床常用的治疗手段。文章将从胸膜硬化剂、抗血管生成药物、铂类化疗药物、生物免疫制剂、中药制剂等研究进展入手，对不同药物治疗恶性胸腔积液的适宜人群及优劣势等方面进行比较分析。文章对目前常用的胸腔内灌注治疗(Intrapleural Perfusion Therapy, IPT)作一综述，旨在为临床治疗方案提供更多选择，促进IPT的规范诊疗和发展。
Abstract: Malignant pleural effusion is one of the common complications of advanced malignant tumors, which can cause chest pain, dyspnea and other symptoms and seriously affect the quality of life of patients. The commonly used clinical treatment method mainly focuses on chest tube drainage of effusion, which can relieve the symptoms of dyspnea in time but now can not treat the problem of pleural effusion generation fundamentally. With the in-depth research on malignant pleural effu-sion, the combination of drug intrathoracic local perfusion on the basis of chest tube drainage of ef-fusion is a common clinical treatment at present. The article will start from the research progress of pleural sclerosing agents, anti-angiogenic drugs, platinum-based chemotherapeutic drugs, bioim-mune agents, and Chinese medicinal agents, and provide a comparative analysis of the appropriate population and advantages and disadvantages of different drugs for the treatment of malignant pleural effusion. The article provides a review of the current commonly used intrathoracic perfusion therapy (IPT), aiming to provide more options for clinical treatment options and promote the standardized treatment and development of IPT.
文章引用：郭晶晶, 雷光焰. 胸腔内灌注治疗肺癌相关胸腔积液的研究进展[J]. 临床医学进展, 2022, 12(6): 5533-5539. https://doi.org/10.12677/ACM.2022.126800

参考文献

[1] Uddin, A. and Chakraborty, S. (2018) Role of miRNAs in Lung Cancer. Journal of Cellular Physiology. (Preprint) [Google Scholar] [CrossRef] [PubMed]
[2] Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7-30. [Google Scholar] [CrossRef] [PubMed]
[3] Wu, Y.B., Xu, L.L., Wang, X.J., Wang, Z., Zhang, J., Tong, Z.H., et al. (2017) Diagnostic Value of Medical Thoracoscopy in Malignant Pleural Ef-fusion. BMC Pulmonary Medicine, 17, Article No. 109. [Google Scholar] [CrossRef] [PubMed]
[4] Ryu, J.S., Ryu, H.J., Lee, S.N., Memon, A., Lee, S.K., Nam, H.S., et al. (2014) Prognostic Impact of Minimal Pleural Effusion in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 32, 960-967. [Google Scholar] [CrossRef] 
[5] Keeratichananont, W., Limthon, T. and Keeratichananont, S. (2015) Efficacy and Safety Profile of Autologous Blood versus Tetracycline Pleurodesis for Malignant Pleural Effusion. Thera-peutic Advances in Respiratory Disease, 9, 42-48. [Google Scholar] [CrossRef] [PubMed]
[6] Usui, K., Sugawara, S., Nishitsuji, M., Fujita, Y., Inoue, A., Mouri, A., et al. (2016) A Phase II Study of Bevacizumab with Carboplatin-Pemetrexed in Non-Squamous Non-Small Cell Lung Carcinoma Patients with Malignant Pleural Effusions: North East Japan Study Group Trial NEJ013A. Lung Cancer, 99, 131-136. [Google Scholar] [CrossRef] [PubMed]
[7] Koegelenberg, C.F.N., Shaw, J.A., Irusen, E.M. and Lee, Y.C.G. (2018) Contemporary Best Practice in the Management of Malignant Pleural Effusion. Therapeutic Advances in Respiratory Disease, 12. [Google Scholar] [CrossRef] [PubMed]
[8] 中国恶性胸腔积液诊断与治疗专家共识组. 恶性胸腔积液诊断与治疗专家共识[J]. 中华内科杂志, 2014, 53(3): 252-256.
[9] American Thoracic Society (2000) Management of Malignant Pleural Effusions. American Journal of Respiratory and Critical Care Medicine, 162, 1987-2001. [Google Scholar] [CrossRef] [PubMed]
[10] Shaw, P. and Agarwal, R. (2004) Pleurodesis for Malignant Pleural Effusions. Cochrane Database of Systematic Reviews, No. 1, Article ID: CD002916. [Google Scholar] [CrossRef] 
[11] Dresler, C.M., Olak, J., Herndon II, J.E., Richards, W.G., Scalzetti, E., Fleishman, S.B., et al. (2005) Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Ma-lignant Pleural Effusion. Chest, 127, 909-915. [Google Scholar] [CrossRef] [PubMed]
[12] Olivares-Torres, C.A., Laniado-Laborín, R., Chávez-García, C., Le-ón-Gastelum, C., Reyes-Escamilla, A. and Light, R.W. (2002) Iodopovidone Pleurodesis for Recurrent Pleural Effusions. Chest, 122, 581-583. [Google Scholar] [CrossRef] [PubMed]
[13] Ibrahim, I.M., Dokhan, A.L., El-Sessy, A.A. and Eltaweel, M.F. (2015) Povidone-Iodine Pleurodesis versus Talc Pleurodesis in Preventing Recurrence of Malignant Pleural Effusion. Journal of Cardiothoracic Surgery, 10, Article No. 64. [Google Scholar] [CrossRef] [PubMed]
[14] Ide, A.G., Baker, N.H. and Warren, S.L. (1939) Vascularization of the Brown Pearce Rabbit Epithelioma Transplant as Seen in the Transparent Ear Chamber. The American Journal of Roentgenology, 42, 891-899.
[15] Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S. and Dvorak, H.F. (1983) Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid. Science, 219, 983-985. [Google Scholar] [CrossRef] [PubMed]
[16] Ferrara, N. and Henzel, W.J. (1989) Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells. Biochemical and Biophysical Research Communications, 161, 851-858. [Google Scholar] [CrossRef] 
[17] Bates, D.O. (2010) Vascular Endothelial Growth Factors and Vascular Permeability. Cardiovascular Research, 87, 262-271. [Google Scholar] [CrossRef] [PubMed]
[18] 刘玉杰, 田攀文. 贝伐珠单抗治疗非小细胞肺癌所致恶性胸腔积液的研究进展[J]. 中国肺癌杂志, 2019, 22(2): 118-124.
[19] Popper, H.H. (2016) Progression and Metastasis of Lung Cancer. Cancer and Metastasis Reviews, 35, 75-91. [Google Scholar] [CrossRef] [PubMed]
[20] 白春学, 陈良安, 胡成平, 李为民, 周建英, 白冲, 宋勇. 晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识(2016年版) [J]. 中华结核和呼吸杂志, 2016, 39(11): 839-849.
[21] Di, W., Yue, C., Ziran, Z., Jie, Z., Jun, N., Ling, D., et al. (2022) A Phase II Study of Bevacizumab in Non-Squamous, Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusion. Future Oncology, 18, 669-677. [Google Scholar] [CrossRef] [PubMed]
[22] Chen, D., Song, X., Shi, F., Zhu, H., Wang, H., Zhang, N., et al. (2017) Greater Efficacy of Intracavitary Infusion of Bevacizumab Compared to Traditional Local Treatments for Patients with Malignant Cavity Serous Effusion. Oncotarget, 8, 35262-35271. [Google Scholar] [CrossRef] [PubMed]
[23] Xu, X., Mao, W., Chen, Q., Zhuang, Q., Wang, L., Dai, J., et al. (2014) Endostar, a Modified Recombinant Human Endostatin, Suppresses Angiogenesis through Inhibition of Wnt/β-Catenin Signaling Pathway. PLOS ONE, 9, e107463. [Google Scholar] [CrossRef] [PubMed]
[24] Fukumoto, S., Morifuji, M., Katakura, Y., Ohishi, M. and Nakamura, S. (2005) Endostatin Inhibits Lymph Node Metastasis by a Down-Regulation of the Vascular Endothelial Growth Factor C Expression in Tumor Cells. Clinical & Experimental Metastasis, 22, 31-38. [Google Scholar] [CrossRef] [PubMed]
[25] Li, K., Shi, M. and Qin, S. (2018) Current Status and Study Pro-gress of Recombinant Human Endostatin in Cancer Treatment. Oncology and Therapy, 6, 21-43. [Google Scholar] [CrossRef] [PubMed]
[26] Qin, S., Yang, L., Liang, J., Cheng, Y., Tan, Q., Bi, J., Wang, L., Hu, B., Shi, J., Sun, G., et al. (2017) Prospective, Randomized, Multicenter Clinical Study of Endometrial and Cisplatin in the Treatment of Malignant Pleural Effusion. Chinese Journal of Clinical Oncology, 22, 193-202.
[27] Rong, B., Cai, X., Liu, H., Gao, W. and Yang, S. (2016) Thoracic Perfusion of Recombinant Human Endostatin (Endostar) Combined with Chemotherapeutic Agents versus Chemotherapeutic Agents alone for Treating Malignant Pleural Effusions: A Sys-tematic Evaluation and Meta-Analysis. BMC Cancer, 16, Article No. 888. [Google Scholar] [CrossRef] [PubMed]
[28] 李业锦. 不同剂量恩度联合顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床分析[J]. 吉林医学, 2019, 40(5): 928-929.
[29] 刘自力, 黄礼年, 王斌, 刘继柱, 刘伟伟. 恩度联合顺铂治疗非小细胞肺癌合并恶性胸腔积液的Meta分析[J]. 中国循证医学杂志, 2016(5): 557-563.
[30] 张树林, 闫其涛. 观察不同剂量顺铂胸腔内注射疗法在肺癌恶性胸腔积液患者中的应用效果[J]. 中国现代药物应用, 2018, 12(23): 68-70.
[31] 徐世新, 姚舒, 陆淑凤. 重组白介素2联合卡铂胸腔内灌注治疗恶性胸腔积液临床观察[J]. 中国当代医药, 2010, 17(34): 61+69.
[32] 陈婧, 李冬雷, 张旭宇, 高玉华, 王艳丽. 贝伐单抗与卡铂结合治疗非小细胞肺癌恶性胸腔积液的疗效[J]. 实用癌症杂志, 2020, 35(2): 208-211.
[33] 朱姝, 刘淮东, 杨秋云, 李娟, 王惠. 奈达铂及顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床疗效及预后对比[J]. 湖南师范大学学报(医学版), 2022, 19(1): 163-166.
[34] 闵诗惠, 郑强强, 张白露, 严丹丽, 王汝兰, 瞿子涵, 等. 洛铂与顺铂胸腔灌注化疗治疗恶性胸腔积液的疗效及不良反应的Meta分析[J]. 中国肺癌杂志, 2019, 22(2): 90-98. [Google Scholar] [CrossRef] [PubMed]
[35] 戴莉莉. 恶性胸腔积液的生物免疫治疗进展[J]. 上海医药, 2011, 32(2): 80-82.
[36] 刘占伟, 卞丹阳, 申国宏, 石磊. 白细胞介素-2联合顺铂治疗肺癌所致恶性胸腔积液[J]. 武警医学院学报, 2007, 16(4): 437-438.
[37] 孙永苹, 汪成琼, 陈玲, 李娜娜, 姚新生, 肖政. 白细胞介素2联合顺铂治疗恶性胸腔积液有效性及安全性的Meta分析[J]. 重庆医学, 2017, 46(1): 84-89+93.
[38] 沈红梅, 黄杰, 段林灿, 王轶珊. 中药制剂胸腔内灌注治疗恶性胸腔积液现状[J]. 山东医药, 2011, 51(32): 110-111.
[39] Lin, Z., Jiang, M., Gao, L. and Zhang, H. (2020) The Clinical Efficacy of Traditional Chinese Medicine in the Treatment of Malignant Pleural Effusion: A Protocol of Systematic Review and Meta-Analysis. Medicine, 99, e22403. [Google Scholar] [CrossRef] 

为你推荐